Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease

Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease patients who have proven β-amyloid pathology (Aβ). One of these, lecanemab, has subsequently received full approval and other monoclonal antibodies are poised for positive review and approval. Anti-amyloid mAbs share the feature of producing a marked reduction in total brain Aβ revealed by amyloid positron emission tomography. Trials associated with slowing of cognitive decline have achieved a reduction in measurable plaque Aβ in the range of 15-25 centiloids; trials of agents that did not reach this threshold were not associated with cognitive…

• AD
  Alzheimer's Drug Discovery Foundation

  Award: P20GM109025
• NI
  National Institute on Aging

  Awards: P20GM109025, P30AG072959, R35AG71476, P20AG068053, R01AG053798
• NI
  National Institute of General Medical Sciences

  Awards: P20AG068053, P20GM109025
• NI
  National Institute of Neurological Disorders and Stroke

  Award: U01NS093334